Literature DB >> 11024319

Calling the shots: immunization finance policies and practices. Executive summary of the report of the Institute of Medicine.

B Guyer1, D R Smith, R Chalk.   

Abstract

Federal, state, and private-sector investments in vaccine purchases and immunization programs are lagging behind emerging opportunities to reduce the risks of vaccine-preventable disease. Although federal assistance to the states for immunization programs and data collection efforts rapidly expanded in the early part of the 1990s, significant cutbacks have occurred in the last 5 years that have reduced the size of state grant awards by more than 50% from their highest point. During this same period, the vaccine delivery system for children and adults has become more complex and fragmented. This combination of new challenges and reduced resources has led to instability in the public health infrastructure that supports the U. S. immunization system. Many states have reduced the scale of their immunization programs and currently lack adequate strength in areas such as data collection among at-risk populations, strategic planning, program coordination, and assessment of immunization status in communities that are served by multiple health care providers. If unmet immunization needs are not identified and addressed, states will have difficulty in achieving the national goal of 90% coverage by the year 2010 for completion of the childhood immunization series for young children. Furthermore, state and national coverage rates, which reached record levels for vaccines in widespread use (79%, 1998), can be expected to decline and preventable disease outbreaks may occur as a result, particularly among persons who are vulnerable to vaccine-preventable disease because of their underimmunization status. The Institute of Medicine (IOM) Committee on Immunization Finance Policies and Practices has therefore concluded that a renewal and strengthening of the federal and state immunization partnership is necessary. The goal of this renewed partnership is to prevent infectious disease; to monitor, sustain, and improve vaccine coverage rates for child and adult populations within more numerous and increasingly diversified health care settings; and to respond to vaccine-safety concerns. To achieve this renewal, states require a consistent strategy, additional funds, and a multiyear finance plan that can help expedite the delivery of new vaccines; strengthen the immunization assessment, assurance, and policy development functions in each state; and adapt childhood immunization programs to serve the needs of new age groups (especially adults with chronic diseases) in different health care environments. The IOM committee recommends that federal and state governments adopt a national finance strategy that would allocate $1.5 billion in federal and state resources over the first 5 years to strengthen the infrastructure for child and adult immunization-an annual increase of $175 million over current spending levels. These resources would consist of $200 million per year in state infrastructure grants awarded by the Centers for Disease Control and Prevention (the Section 317 program) and an additional $100 million per year in increased state contributions. The committee also recommends that the Congress replace the current discretionary Section 317 grants with a formula approach for state immunization grant awards to improve the targeting and stability of federal immunization grants. The formula should provide a base level of support to all states, as well as additional amounts related to each state's need, capacity, and performance. The committee further recommends that Congress introduce a state match requirement for the receipt of increased federal funds to help strengthen and stabilize the infrastructure that supports long-term public health assessment, assurance, and policy development efforts. (ABSTRACT TRUNCATED)

Entities:  

Mesh:

Year:  2000        PMID: 11024319     DOI: 10.1016/s0749-3797(00)00212-9

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  10 in total

1.  Setting prices for new vaccines (in advance).

Authors:  Thomas G McGuire
Journal:  Int J Health Care Finance Econ       Date:  2003-09

2.  Impact of the CDC's Section 317 Immunization Grants Program funding on childhood vaccination coverage.

Authors:  David B Rein; Amanda A Honeycutt; Lucia Rojas-Smith; James C Hersey
Journal:  Am J Public Health       Date:  2006-07-27       Impact factor: 9.308

3.  Immunity for the people: the challenge of achieving high vaccine coverage in American history.

Authors:  James Colgrove
Journal:  Public Health Rep       Date:  2007 Mar-Apr       Impact factor: 2.792

4.  What can HIV vaccine trials teach us about future HIV vaccine dissemination?

Authors:  Peter A Newman; Naihua Duan; Lisa Kakinami; Kathleen Roberts
Journal:  Vaccine       Date:  2008-03-28       Impact factor: 3.641

5.  Impact of state vaccine financing policy on uptake of heptavalent pneumococcal conjugate vaccine.

Authors:  Shannon Stokley; Kate M Shaw; Lawrence Barker; Jeanne M Santoli; Abigail Shefer
Journal:  Am J Public Health       Date:  2006-05-30       Impact factor: 9.308

6.  Preparing for the availability of a partially effective HIV vaccine: some lessons from other licensed vaccines.

Authors:  Robert T Chen; Dale J Hu; Eileen Dunne; Michael Shaw; James I Mullins; Supachai Rerks-Ngarm
Journal:  Vaccine       Date:  2011-07-13       Impact factor: 3.641

7.  Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic.

Authors:  Anna M Acosta; Chas DeBolt; Azadeh Tasslimi; Melissa Lewis; Laurie K Stewart; Lara K Misegades; Nancy E Messonnier; Thomas A Clark; Stacey W Martin; Manisha Patel
Journal:  Pediatrics       Date:  2015-05-04       Impact factor: 7.124

8.  HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics.

Authors:  Peter A Newman; Naihua Duan; Sung-Jae Lee; Ellen T Rudy; Danielle S Seiden; Lisa Kakinami; William E Cunningham
Journal:  Vaccine       Date:  2005-11-21       Impact factor: 3.641

9.  Childhood vaccine purchase costs in the public sector: past trends, future expectations.

Authors:  Matthew M Davis; Jessica L Zimmerman; John R C Wheeler; Gary L Freed
Journal:  Am J Public Health       Date:  2002-12       Impact factor: 9.308

10.  An Estimation of Private Household Costs to Receive Free Oral Cholera Vaccine in Odisha, India.

Authors:  Vittal Mogasale; Shantanu K Kar; Jong-Hoon Kim; Vijayalaxmi V Mogasale; Anna S Kerketta; Bikash Patnaik; Shyam Bandhu Rath; Mahesh K Puri; Young Ae You; Hemant K Khuntia; Brian Maskery; Thomas F Wierzba; Binod Sah
Journal:  PLoS Negl Trop Dis       Date:  2015-09-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.